.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,641,805

« Back to Dashboard
Patent 5,641,805 protects PATANOL and is included in one NDA. There has been one Paragraph IV challenge on Patanol. There are six tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for PATANOL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-three patent family members in nineteen countries.

Summary for Patent: 5,641,805

Title: Topical ophthalmic formulations for treating allergic eye diseases
Abstract:Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
Inventor(s): Hayakawa; Eiji (Susono, JP), Nakakura; Masashi (Shizuoka-ken, JP), Robertson; Stella M. (Arlington, TX), Yanni; John Michael (Burleson, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX) Kyowa Hakko Kogyo Co. Ltd. (Tokyo, JP)
Application Number:08/469,729
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Alcon
PATANOL
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC020688-001Dec 18, 1996RXYes5,641,805*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,641,805

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria220906► subscribe
Australia5726196► subscribe
Australia698854► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc